SCHEMBL6493934

SCHEMBL6493934

CCCCc1cn(-c2c(C)cccc2F)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1

nearest known ligand 0.53

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 8/20 0.53
AGTR2 P50052 8/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493252 0.98 AGTR1 (0.51) AGTR1AGTR2
SCHEMBL6490702 0.95 AGTR1 (0.47) AGTR1AGTR2
SCHEMBL6501578 0.95 AGTR1 (0.51) AGTR1AGTR2
SCHEMBL6490616 0.94 AGTR1 (0.59) AGTR1AGTR2
SCHEMBL6494509 0.93 AGTR1 (0.48) AGTR1AGTR2
SCHEMBL8119141 0.92 AGTR1 (0.49) AGTR1AGTR2
SCHEMBL6499547 0.92 AGTR1 (0.48) AGTR1AGTR2
SCHEMBL6503046 0.92 AGTR1 (0.52) AGTR1AGTR2
SCHEMBL6491991 0.92 AGTR1 (0.54) AGTR1AGTR2
SCHEMBL6491440 0.92 AGTR1 (0.56) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040048911-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G. D. SEARLE & CO. 2004-03-11 US claimed
US-20020038035-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO. 2002-03-28 US claimed
EP-0690854-B1 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS SEARLE & CO (US) 2000-07-12 EP claimed
EP-0978515-A2 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists G.D. SEARLE & CO. (US) 2000-02-09 EP claimed
WO-1994021629-A1 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1994-09-29 WO claimed
US-6858636-B2 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO. (US) 2005-02-22 US disclosed
US-20040048911-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G. D. SEARLE & CO. 2004-03-11 US disclosed
US-6630497-B2 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO 2003-10-07 US disclosed
US-20020038035-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO. 2002-03-28 US disclosed
EP-0690854-B1 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS SEARLE & CO (US) 2000-07-12 EP disclosed
EP-0978515-A2 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists G.D. SEARLE & CO. (US) 2000-02-09 EP disclosed
WO-1994021629-A1 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1994-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038035-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders AGTR1, AGTR2, REN AGTR1 1/4885AGTR2 2/4885
US-20040048911-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders AGTR1, AGTR2, REN AGTR1 1/4885AGTR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.